887585-99-1 Usage
Uses
Used in Pharmaceutical Research:
(4-bromo-2,6-difluorophenyl)methanamine is used as a building block for creating other chemical compounds, particularly in the development of new drugs. Its unique structure and reactivity contribute to the design and synthesis of potential therapeutic agents.
Used in Agrochemical Development:
(4-bromo-2,6-difluorophenyl)methanamine also has potential applications in the development of new agrochemicals, where its specific chemical properties can be leveraged to create effective and targeted products for agricultural use.
Used in Organic Synthesis:
As a reagent in chemical reactions, (4-bromo-2,6-difluorophenyl)methanamine is used for the production of various organic compounds. Its versatility in synthesis allows for the creation of a wide range of molecules for different applications across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 887585-99-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,7,5,8 and 5 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 887585-99:
(8*8)+(7*8)+(6*7)+(5*5)+(4*8)+(3*5)+(2*9)+(1*9)=261
261 % 10 = 1
So 887585-99-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H6BrF2N/c8-4-1-6(9)5(3-11)7(10)2-4/h1-2H,3,11H2
887585-99-1Relevant articles and documents
PHOSPHODIESTERASE INHIBITORS AND USE
-
, (2021/04/02)
The invention provides compounds that may inhibits to ENPP1, and are accordingly useful for treatment disorders related to ENPP1. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent disorders related to ENPP1.
PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER
-
Paragraph 00224; 00454; 00455, (2017/05/02)
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of t
BRIDGED BICYCLIC KALLIKREIN INHIBITORS
-
, (2016/12/26)
Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.